1-12 of 12
Xuan Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

829-P: iGlarLixi vs. Basal-Bolus (BB) or Premixed Insulin in Older Adult Ethnic Minorities with Type 2 Diabetes (T2D)

GUILLERMO UMPIERREZ, JASVINDER GILL, DAVID HOOD, XUAN LI, ANA NÚÑEZ
Journal: Diabetes
Diabetes 2024;73(Supplement_1):829-P
https://doi.org/10.2337/db24-829-P
Published: 14 June 2024
View article titled, 829-P: iGlarLixi vs. Basal-Bolus (BB) or Premixed Insulin in Older Adult Ethnic Minorities with Type 2 Diabetes (T2D)
Meeting Abstracts

1880-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Non-Asian People with Type 2 Diabetes Inadequately Controlled with Basal Insulin—A Systemic Literature Review and Network Meta-analysis

PHILIP HOME, FELIPE LAUAND, KHIER DJABALLAH, FRANCOIS BOURHIS, XUAN LI, KHADIJA HAFIDH, ROOPA MEHTA, KHADRA FARAOUN, INAN ANAFOROGLU, MIR-MASOUD POURRAHMAT
Journal: Diabetes
Diabetes 2024;73(Supplement_1):1880-LB
https://doi.org/10.2337/db24-1880-LB
Published: 14 June 2024
View article titled, 1880-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Non-Asian People with Type 2 Diabetes Inadequately Controlled with Basal Insulin—A Systemic Literature Review and Network Meta-analysis
Meeting Abstracts

1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes—Soli De-escalation

FRANCESCO GIORGINO, FELIPE LAUAND, SR., SORALY SERVERA, XUAN LI, ZOLTÁN TAYBANI, ALICE Y.Y. CHENG, VIVIAN FONSECA, AMAR TEBAIBIA, INAN ANAFOROGLU
Journal: Diabetes
Diabetes 2024;73(Supplement_1):1867-LB
https://doi.org/10.2337/db24-1867-LB
Published: 14 June 2024
View article titled, 1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes—Soli De-escalation
Meeting Abstracts

156-LB: Nursing Burden Administering/Monitoring Complex Insulin Regimens vs. Basal Insulin/GLP-1 RA Fixed-Ratio Combinations (FRCs) for People with Type 2 Diabetes (PWT2D) in Long-Term Care (LTC)

HARLEY E. DAVIDSON, ASHLEY NELSON, LISA F. HAN, MELISSA LAMANTIA, KERRY DESAI, XUAN LI, TERRY A. DEX, JACQUELINE F. VANCE, KEVIN OVERBECK
Journal: Diabetes
Diabetes 2023;72(Supplement_1):156-LB
https://doi.org/10.2337/db23-156-LB
Published: 20 June 2023
View article titled, 156-LB: Nursing Burden Administering/Monitoring Complex Insulin Regimens vs. Basal Insulin/GLP-1 RA Fixed-Ratio Combinations (FRCs) for People with Type 2 Diabetes (PWT2D) in Long-Term Care (LTC)
Journal Articles

Neutrophil Extracellular Traps Induce Glomerular Endothelial Cell Dysfunction and Pyroptosis in Diabetic Kidney Disease

Fengfan Zheng, Linqiang Ma, Xuan Li, Zhihong Wang, Rufei Gao, Chuan Peng, Bing Kang, Yue Wang, Ting Luo, Jinshan Wu, Yi Yang, Lilin Gong, Qifu Li, Shumin Yang, Jinbo Hu
Journal: Diabetes
Diabetes 2022;71(12):2739–2750
https://doi.org/10.2337/db22-0153
Published: 12 September 2022
View article titled, Neutrophil Extracellular Traps Induce Glomerular Endothelial Cell Dysfunction and Pyroptosis in Diabetic Kidney Disease
Open the PDF for Neutrophil Extracellular Traps Induce Glomerular Endothelial Cell Dysfunction and Pyroptosis in Diabetic Kidney Disease in another window
Meeting Abstracts

260-OR: iGlarLixi vs. Basal plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study

RORY J. MCCRIMMON, ALICE Y. CHENG, GAGIK R. GALSTYAN, KHIER DJABALLAH, XUAN LI, MATHIEU COUDERT, JUAN PABLO FRIAS
Journal: Diabetes
Diabetes 2022;71(Supplement_1):260-OR
https://doi.org/10.2337/db22-260-OR
Published: 01 June 2022
View article titled, 260-OR: iGlarLixi vs. Basal plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study
Meeting Abstracts

812-P: Real-World Persistence, Adherence, Health Care Resource Utilization (HRU), and Hypoglycemia in People with Type 2 Diabetes (T2D) Continuing the 2nd-Generation (2nd-Gen) Basal Insulin (BI) (Glargine 300 U/mL [Gla-300]) vs. Switching to a 1st-Generation (1st-Gen) BI (Glargine 100 U/mL [Gla-100] or Detemir [IDet 100 U/mL])

STEVEN EDELMAN, JENNIFER D. GOLDMAN, DANIEL C. MALONE, RON PREBLICK, KOVIDA MUNAGA, XUAN LI, JASVINDER GILL, SUMANA GANGI
Journal: Diabetes
Diabetes 2022;71(Supplement_1):812-P
https://doi.org/10.2337/db22-812-P
Published: 01 June 2022
View article titled, 812-P: Real-World Persistence, Adherence, Health Care Resource Utilization (HRU), and Hypoglycemia in People with Type 2 Diabetes (T2D) Continuing the 2nd-Generation (2nd-Gen) Basal Insulin (BI) (Glargine 300 U/mL [Gla-300]) vs. Switching to a 1st-Generation (1st-Gen) BI (Glargine 100 U/mL [Gla-100] or Detemir [IDet 100 U/mL])
Meeting Abstracts

739-P: iGlarLixi vs. Premixed Insulin Initiation in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: SoliComplex Real-World Study

ROSEMARIE LAJARA, CAROLINE HELLER, KEVIN M. PANTALONE, ELISHEVA LEW, XUAN LI, TERRY A. DEX, RACHEL KILPATRICK
Journal: Diabetes
Diabetes 2022;71(Supplement_1):739-P
https://doi.org/10.2337/db22-739-P
Published: 01 June 2022
View article titled, 739-P: iGlarLixi vs. Premixed Insulin Initiation in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: SoliComplex Real-World Study
Meeting Abstracts

733-P: Initiation of iGlarLixi vs. Basal-Bolus Insulin (BB) in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: The SoliComplex Real-World Study

KEVIN M. PANTALONE, CAROLINE HELLER, ROSEMARIE LAJARA, ELISHEVA LEW, XUAN LI, TERRY A. DEX, RACHEL KILPATRICK
Journal: Diabetes
Diabetes 2022;71(Supplement_1):733-P
https://doi.org/10.2337/db22-733-P
Published: 01 June 2022
View article titled, 733-P: Initiation of iGlarLixi vs. Basal-Bolus Insulin (BB) in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: The SoliComplex Real-World Study
Meeting Abstracts

103-LB: Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 1

EUGENE WRIGHT, JASVINDER GILL, SAMUEL HUSE, XUAN LI, TIMOTHY REID, FANG L. ZHOU
Journal: Diabetes
Diabetes 2021;70(Supplement_1):103-LB
https://doi.org/10.2337/db21-103-LB
Published: 01 June 2021
View article titled, 103-LB: Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 1
Journal Articles

Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice

Xiaodong Sun, Fang Han, Qingguo Lu, Xuan Li, Di Ren, Jingwen Zhang, Ying Han, Yang K. Xiang, Ji Li
Journal: Diabetes
Diabetes 2020;69(6):1292–1305
https://doi.org/10.2337/db19-0991
Published: 31 March 2020
View article titled, Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice
Open the PDF for Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice in another window
Meeting Abstracts

2096-P: Real-World Examination of Lorcaserin Treatment in Patients with Type 2 Diabetes, Prediabetes, and Metabolic Syndrome

SAMANTHA R. HARRIS, RUSSELL L. KNOTH, XUAN LI, IBRAHIM KHILFEH, JIYOON CHOI, ATHENA PHILIS-TSIMIKAS, KEN FUJIOKA
Journal: Diabetes
Diabetes 2019;68(Supplement_1):2096-P
https://doi.org/10.2337/db19-2096-P
Published: 01 June 2019
View article titled, 2096-P: Real-World Examination of Lorcaserin Treatment in Patients with Type 2 Diabetes, Prediabetes, and Metabolic Syndrome